biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
IO Biotech projects
5 ClinicalTrials.gov programs sponsored by IO Biotech.
IO Biotech has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IRX4204
IO Biotech
Lung Cancer, Nonsmall Cell
1 trial -
IRX4204
IO Biotech
Parkinson's Disease
1 trial -
IRX5183
IO Biotech
Acute Myeloid Leukemia (AML)
1 trial -
PD-L1/IDO Peptide Vaccine
IO Biotech
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
1 trial -
SC201 (VICTORIA-01)
IO Biotech
advanced/metastatic solid tumors
1 trial
Frequently asked questions
How many clinical projects does IO Biotech have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.